Dicerna Pharmaceuticals
Pharmaceuticals, 87 Cambridgepark Dr Fl 2, Lexington, Massachusetts, 02140, United States, 201-500 Employees
Phone Number: 61********
Who is DICERNA PHARMACEUTICALS
Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribu...
Read More
-
Headquarters: 87 Cambridgepark Dr Fl 2, Lexington, Massachusetts, 02140, United States
-
Date Founded: 2007
-
Employees: 201-500
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from DICERNA PHARMACEUTICALS
Dicerna Pharmaceuticals Org Chart and Mapping
Email
Phone
Similar Companies to Dicerna Pharmaceuticals
Agios Pharmaceuticals
-
201-500
-
$ 10 Million to 25 Million
Alnylam Pharmaceuticals
-
1001-5000
-
$ 500 Million to 1 Billion
Axcella
-
51-200
-
$ 250 Million to 500 Million
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Dicerna Pharmaceuticals
Answer: Dicerna Pharmaceuticals's headquarters are located at 87 Cambridgepark Dr Fl 2, Lexington, Massachusetts, 02140, United States
Answer: Dicerna Pharmaceuticals's phone number is 61********
Answer: Dicerna Pharmaceuticals's official website is https://dicerna.com
Answer: Dicerna Pharmaceuticals's revenue is $100 Million to $250 Million
Answer: Dicerna Pharmaceuticals's SIC: 2834
Answer: Dicerna Pharmaceuticals's NAICS: 325412
Answer: Dicerna Pharmaceuticals has 201-500 employees
Answer: Dicerna Pharmaceuticals is in Pharmaceuticals
Answer: Dicerna Pharmaceuticals top competitors include: Agios Pharmaceuticals , Alnylam Pharmaceuticals , Axcella
Answer: Dicerna Pharmaceuticals contact info: Phone number: 61******** Website: https://dicerna.com
Answer: Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease. Using our proprietary GalXCTM and GalXC-PlusTM RNAi technologies, we discover and develop innovative RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, our GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, we have continued to innovate and are exploring new applications of our RNAi technology with GalXC-Plus, which expands on the functionality and application of our flagship liver-targeted GalXC technology to tissues and cell types outside the liver with the potential to treat diseases across multiple therapeutic areas. Our team brings together talented experts across the fields of biology, chemistry, clinical science, medicine and more. With decades of scientific and technical experience focused on RNAi technology, we have the knowledge and experience needed to discover and develop therapies for patients with serious unmet medical needs. Between our own pipeline of core discovery and clinical candidates and those developed through collaborative relationships with some of the worlds leading pharmaceutical companies, we have generated more than 20 active discovery, preclinical or clinical proprietary and collaborative programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month